Evidence map›Paper›PMID 37328842›Full record

ArticleCancer cell international2023

High FAAP24 expression reveals poor prognosis and an immunosuppressive microenvironment shaping in AML.

Xiebing Bao, Jingyun Chi, Yiwei Zhu, Minfeng Yang, Jiahui Du, Zaixiang Tang, Xiaogang Xu, Genxiang Mao, Zhibing Wu, Jun Chen and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer cell international, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 2 countries.

Xiebing Bao *National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China.
Jingyun Chi *Suzhou Key Laboratory of Medical Biotechnology, Suzhou Vocational Health College, 28 Kehua Road, Suzhou, 215009, China.
Yiwei Zhu *Suzhou Medical College, Soochow University, Suzhou, 215006, China.
Minfeng YangDepartment of Health Technology and Informatics, The Hong Kong Polytechnic University, Kowloon, Hong Kong SAR, P.R. China.
Jiahui DuSuzhou Key Laboratory of Medical Biotechnology, Suzhou Vocational Health College, 28 Kehua Road, Suzhou, 215009, China.
Zaixiang TangDepartment of Biostatistics, School of Public Health, Medical College of Soochow University, Suzhou, 215123, China.
Xiaogang XuZhejiang Provincial Key Lab of Geriatrics & Geriatrics Institute of Zhejiang Province, Affiliated Zhejiang Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, 310058, China.
Genxiang MaoZhejiang Provincial Key Lab of Geriatrics & Geriatrics Institute of Zhejiang Province, Affiliated Zhejiang Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, 310058, China.
Zhibing WuDepartment of Oncology, Affiliated Zhejiang Hospital, Zhejiang University School of Medicine, Hangzhou, 310013, China.
Jun ChenZhejiang Provincial Key Lab of Geriatrics & Geriatrics Institute of Zhejiang Province, Affiliated Zhejiang Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, 310058, China.
Jingsheng HuaDepartment of Hematology, Taizhou Municipal Hospital Affiliated to Taizhou University, Taizhou, 318000, China. huajingsheng@sohu.com.
Ting XuNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China. xuting83_xuye@163.com.
Song-Bai LiuSuzhou Key Laboratory of Medical Biotechnology, Suzhou Vocational Health College, 28 Kehua Road, Suzhou, 215009, China. liusongbai@126.com.
Soochow University · CNSuzhou Vocational Health College · CNZhejiang University · CNHong Kong Polytechnic University · HKTaizhou Municipal Hospital · CNZhejiang Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAs a core member of the FA complex, in the Fanconi anemia pathway, FAAP24 plays an important role in DNA damage repair. However, the association between FAAP24 and patient prognosis in AML and immune infiltration remains unclear. The purpose of this study was to explore its expression characteristics, immune infiltration pattern, prognostic value and biological function using TCGA-AML and to verify it in the Beat AML cohort.

methodsIn this study, we examined the expression and prognostic value of FAAP24 across cancers using data from TCGA, TARGET, GTEx, and GEPIA2. To further investigate the prognosis in AML, development and validation of a nomogram containing FAAP24 were performed. GO/KEGG, ssGSEA, GSVA and xCell were utilized to explore the functional enrichment and immunological features of FAAP24 in AML. Drug sensitivity analysis used data from the CellMiner website, and the results were confirmed in vitro.

resultsIntegrated analysis of the TCGA, TARGET and GTEx databases showed that FAAP24 is upregulated in AML; meanwhile, high FAAP24 expression was associated with poor prognosis according to GEPIA2. Gene set enrichment analysis revealed that FAAP24 is implicated in pathways involved in DNA damage repair, the cell cycle and cancer. Components of the immune microenvironment using xCell indicate that FAAP24 shapes an immunosuppressive tumor microenvironment (TME) in AML, which helps to promote AML progression. Drug sensitivity analysis showed a significant correlation between high FAAP24 expression and chelerythrine resistance. In conclusion, FAAP24 could serve as a novel prognostic biomarker and play an immunomodulatory role in AML.

conclusionsIn summary, FAAP24 is a promising prognostic biomarker in AML that requires further exploration and confirmation.

Indexed as

AMLChelerythrineFAAP24ImmunosuppressionPrognosis

Identifiers

PMID37328842
PMCPMC10276373
OpenAlexW4381046799

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.